PMID: 7528162Jul 1, 1994Paper

Alternating chemotherapy regimen (P-VABEC) for intermediate and high-grade non-Hodgkin's lymphoma of the middle aged and elderly

Hematological Oncology
F CaraccioloB Grassi

Abstract

An intensive third generation regimen (P-VABEC) including adriamycin, etoposide, cyclophosphamide, vincristine, bleomycin and prednisolone was administered to 43 unselected elderly patients with intermediate or high-grade non-Hodgkin's lymphomas (NHL). The median age was 67, 40 per cent were Ann Arbor stage IV, 73 per cent had 'B' symptoms, 55 per cent had bulky disease, 48 per cent had serum lactate dehydrogenase greater than 450 U/l, 85 per cent had serum thymidine-kinase greater than 4 U/l. Thirty patients were previously untreated. The complete remission (CR) rate was 74 per cent, and the partial remission (PR) rate 23 per cent, with an overall response rate of 97 per cent. The regimen was carried out on an outpatient basis in all patients. No death occurred during therapy. The Kaplan-Meier actuarial survival of all patients at 3-years is 47 per cent, and 50 per cent (16/32) of all patients who attained CR remain alive and in remission at a median of 21+ months (range 6+ to 42+). These results confirm that high remission and failure-free survival rates can be achieved also in elderly unselected patients with aggressive NHL treated with curative intent.

References

Jan 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A M SchneiderB D Clarkson
Jan 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L LongoR I Fisher
May 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E O'ReillyJ M Connors
Jan 1, 1991·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J O Armitage
Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U TirelliS Monfardini
Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R M MeyerM D Goodyear
Nov 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L LongoR C Young
Jun 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L W KwakS J Horning
Mar 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D B BoydD McDermott
Dec 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M VoseJ Mailliard
Nov 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U TirelliW P Breed
Mar 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D O DixonH E Wilson
Apr 1, 1984·Journal of the American Geriatrics Society·J O Armitage, J F Potter
Dec 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MartelliF Mandelli
Jan 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H C SchoutenA H Goldstone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.